{"generated_at":"2026-09-05T23:47:22.184Z","count":23,"rows":[{"rubric_key":"FID","title":"Fiduciary duty and loyalty","model_section":"Section 2.4","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"DISC","title":"Full disclosure of compensation and conflicts","model_section":"Sections 2.4, 2.6","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"OWN","title":"Ownership and affiliate disclosure exhibit","model_section":"Proposed Exhibit A-5","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"DEF","title":"Definitions that close loopholes","model_section":"Section 1","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"PASS","title":"100% pass-through of manufacturer revenue","model_section":"Section 4","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"NAC","title":"Affiliate pharmacy pricing at acquisition cost","model_section":"Section 3.2","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"CEIL","title":"Benchmark ceiling and cheapest lawful option","model_section":"Section 3.3","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"CASH","title":"Cash price protection and deductible credit","model_section":"Section 3.4","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"MAC","title":"MAC list governance","model_section":"Section 3.5","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"SPRD","title":"No spread pricing","model_section":"Sections 2.5, 3.1, 3.5","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"GPO","title":"GPO and purchasing entity pass-through","model_section":"Section 5","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"FORM","title":"Plan sponsor controls the formulary","model_section":"Section 6","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"LNC","title":"Lowest net cost standard and book of business comparison","model_section":"Section 6","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"NET","title":"Pharmacy network protections and anti-steering","model_section":"Section 7","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"MFN","title":"Most favored pricing and market check","model_section":"Section 8","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"AUD","title":"Audit rights, data access and reporting","model_section":"Section 9","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"DATA","title":"Plan sponsor owns all plan data","model_section":"Sections 9.4, 9.5","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"PERF","title":"Performance guarantees with real remedies","model_section":"Section 10","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"ENF","title":"Self executing enforcement and two strikes exit","model_section":"Sections 10, 12.5","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"AMD","title":"Amendments only in writing","model_section":"Section 11","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"TERM","title":"Termination without penalty","model_section":"Section 12","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"SPEC","title":"Specialty drug pricing controls","model_section":"Sections 1.16, 3.2(d)","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0},{"rubric_key":"GAG","title":"Gag clause (red flag)","model_section":"Sections 9, 14","accepted":0,"accepted_with_edits":0,"rejected":0,"no_response":0,"not_raised":0,"total":0}],"license":"Public record. Attribution appreciated: BetterBuy Rx PBM Commons, betterbuyrx.com/commons"}